Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CB | P42338 | 20/20 | 0.72 |
| ▸ | PIK3CD | O00329 | 9/20 | 0.72 |
| ▸ | PIK3CA | P42336 | 9/20 | 0.72 |
| ▸ | PIK3CG | P48736 | 9/20 | 0.72 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.69 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.69 |
| ▸ | ERN2 | Q76MJ5 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27221170 | 0.90 | PIK3CB (0.73) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL29826778 | 0.90 | PIK3CB (0.73) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL24713614 | 0.90 | PIK3CB (0.66) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL24714305 | 0.86 | PIK3CB (0.68) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL24713826 | 0.86 | PIK3CB (0.67) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL24713615 | 0.85 | PIK3CB (0.78) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL1639382 | 0.84 | PIK3CB (0.83) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL30768037 | 0.84 | PIK3CB (0.74) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL1638151 | 0.84 | PIK3CB (1.00) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL24714319 | 0.83 | PIK3CB (0.71) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240166617-A1 | PHOSPHOINOSITIDE 3 KINASE BETA INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | GEODE THERAPEUTICS INC (US) | 2024-05-23 | — | — | US | claimed |
| US-20240166617-A1 | PHOSPHOINOSITIDE 3 KINASE BETA INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | GEODE THERAPEUTICS INC (US) | 2024-05-23 | — | — | US | disclosed |
| WO-2022164812-A1 | PHOSPHOINOSITIDE 3 KINASE BETA INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | GEODE THERAPEUTICS INC. (US) | 2022-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240166617-A1 | PHOSPHOINOSITIDE 3 KINASE BETA INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | PIK3CA, PIK3CB, PI4KA | PIK3CB 2/4885PIK3CD 4/4885PIK3CA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.